There are 2789 resources available
1663P - Prognostic impact of baseline neutrophil-to-lymphocyte ratio (NLR) and its change during treatment for overall survival in advanced SCLC
Presenter: MASASHI ISHIHARA
Session: ePoster Display
1665TiP - High-dose vs standard-dose thoracic radiotherapy for extensive stage small cell lung cancer: Study protocol for a phase III randomized trial
Presenter: Yufan Yang
Session: ePoster Display
1666TiP - Phase II study of berzosertib (M6620) + topotecan in patients with relapsed platinum-resistant SCLC: DDRiver SCLC 250
Presenter: Anish Thomas
Session: ePoster Display
1667TiP - Durvalumab plus platinum-etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A Spanish phase IIIb single arm, real-world study
Presenter: Luis Paz-Ares
Session: ePoster Display
1668TiP - Phase Ib study of AMG 757, a half-life extended bispecific T-cell engager immuno-oncology therapy, combined with AMG 404, an anti-PD-1 antibody, in patients with small cell lung cancer (SCLC)
Presenter: Afshin Dowlati
Session: ePoster Display
1673P - Efficacy and safety of 5 mg olanzapine for the prevention of carboplatin-induced nausea and vomiting in patients with thoracic malignancies: A prospective multicenter phase II study
Presenter: Yukiyoshi Fujita
Session: ePoster Display
1674P - Does body mass index (BMI) affect the type of response to anamorelin (ANAM) over time? Focus on body composition and anorexia symptoms and concerns
Presenter: David Currow
Session: ePoster Display
1675P - Potential effect of adipose tissue distribution on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients (pts) receiving first-line pembrolizumab (PEMBRO)
Presenter: Ilaria Trestini
Session: ePoster Display